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When a patient has remained free from seizures for several years while taking antiepileptic drugs (AEDI the 
question arises whether or not the medication can be withdrawn. Therefore it would be desirable to be able to 
identify reliably those patients who will remain seizure-free without reatment. Numerous variables might be 
of prognostic importance but our knowledge about the significance of demographic, genetic, aetiological, 
pathophysiological and treatment-related factors remains extremely poor. Although an abnormal inter-ictal 
EEG has been repeatedly cited as predictive of relapse during and after AED withdrawal, there is little 
evidence to support his view. There is a need for more precise individual prediction of risk but as long as 
patients with forms of epilepsy with widely varying prognosis are grouped together in AED withdrawal trials 
the outcome of these trials will never each consensus about he relapse risk and about he possibility of predict 
relapse in individual patients. 
e 
Key words: epilepsy; antiepileptic drug withdrawal; EEG; prognostic index. 
INTRODUCTION 
There are marked isagreements in the figures 
published both for the probability of patients 
with epilepsy becoming seizure-free on medi- 
cation and for avoiding relapse when it is with- 
drawn. The discrepancies are largely explained 
by different populations tudied and different 
definitions used for epilepsy. 
Becoming seizure-free on medication 
In general, longitudinal or community-based 
surveys suggest a favourable prognoisis for 
remission, up to 70% of patients becoming seiz- 
ure-free 1-6. In a longitudinal study of newly 
diagnosed adult epileptic patients, over 80% 
were seizure-free within 8 years 4'5. By con- 
trast, cross-sectional studies in epileptological 
practice, based as they are on selected groups 
of patients with severe epilepsy, suggest a less 
favourable outcome, only 30-40% of adults 
becoming seizure-free, which means no seiz- 
ures for at least two years 7's. A further diffi- 
culty is presented by patients with a history of 
a single seizure, one third of whom immedi- 
ately receive antiepileptic drug {AED) ther- 
apy 9, so that it is impossible to determine what 
proportion would have suffered further seiz- 
ures without medication. The apparent effect 
of age at onset of epilepsy will also depend 
upon the population studied. In institutional- 
ized patients and those attending special 
centres for epilepsy, early seizure onset implies 
a poor prognosis for remission. In contrast, in 
less severely affected groups childhood onset is 
a favourable feature, particularly when febrile 
convulsions, absence attacks or benign child- 
hood epilepsy are included. Indeed the long- 
term pattern of seizure control seems to be 
largely established uring the first 2 years of 
treatment lo,11 
Remaining seizure-free during and after 
withdrawal of AEDs 
A similar disagreement is found in the litera- 
ture concerning prognosis for remaining 
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seizure-free when AEDs are withdrawn. Re- 
ported recurrence rates range from 6% to over 
60% 12-59. With a worldwide prevalence be- 
tween 1-2% the epilepsies are the second most 
common group of neurological disorders 6. The 
decision to withdraw antiepileptic drugs in 
seizure-free patients must take into account 
the natural history of the different epilepsies 
including the less-known history of the 
untreated epilepsies. Since the introduction of 
bromides in 1857 and the availability ofpheno- 
barbitone and phenytoin in 1912 and 1939, 
respectively, the majority of patients have 
been treated. 
Motivation to discontinue medication 
When a patient, who has previously had epi- 
leptic seizures, has remained free from attacks 
for several years while taking anticonvulsant 
medication, the question arises whether the 
epilepsy has burnt itself out and therefore the 
medication can be withdrawn. The advantages 
are evident: a dose reduction means fewer side- 
effects and less risk of teratogenesis; successful 
discontinuation eliminates the risk of idiosyn- 
cratic reactions, helps to remove the stigma of 
epilepsy an([ confers greater social freedom. 
Some patients may be unwilling to risk further 
epileptic seizures particularly if they have a 
driving licence and choose to continue medi- 
cation, possibly at a reduced dose. Others find 
the drugs so troublesome that they would 
prefer to stop them, if at all possible. 
Patients are particularly motivated to dis- 
continue medication if suffering side-effects. 
Acute idiosyncratic and dose-related rug in- 
toxications are rarely a problem for this emi- 
nently therapy-sensitive group, and chronic 
side effects such as gingival hypertrophy, hir- 
sutism and fatigue will only in rare cases be an 
incentive for attempting withdrawal. 
There are, however, increasingly well- 
documented chronic toxic effects ~°-64. Late 
side-effects must be taken into account, par- 
ticularly in young patients with a long life 
expectancy: in women of reproductive age 
because antiepileptic drugs have teratogenic 
effects 5-~2 and in males because of the possi- 
bility of reduced fertility 73. There is evidence 
that AEDs may have negative effects on the 
central nervous system such as behaviourial 
disorders (phenobarbitone) and pseudo- 
dementia (phenytoin), even in so called 'thera- 
peutic' dosages 74-77. Drug interactions and 
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liver enzyme induction may also give rise to 
problems 7s. 
WITHDRAWAL OF ANTIEPILEPTIC DRUGS IN 
SUCCESSFULLY TREATED PATIENTS WITH 
EPILEPSY 
The results of withdrawing antiepileptic medi- 
cation in patients who have previously had epi- 
leptic seizures, but who have become seizure- 
free during treatment have been the subject of 
several studies (Table 1). The rate of recur- 
rence (i.e. seizures, including aura's within 2 
years after AED withdrawal) varies widely be- 
tween 6cA :~° and over  60~ 39'43"4'5'47. 
The reason for these differences is to be 
found in the heterogeneity of the patient popu- 
lations studied and perhaps also in the 
methods of withdrawing medication. It would 
be highly desirable to be able to identify re- 
liably those patients who will remain seizure- 
free without treatment. Therefore, the 
question arises whether there are any criteria 
that would reliably differentiate the patient 
who is likely to remain seizure-free from one 
who will relapse. 
PREDICTION OF OUTCOME 
Concerning prediction of outcome, again there 
is little agreement. Certain specific syndromes, 
notably benign epilepsy of childhood ls'31 and 
childhood absence pilepsy without associated 
tonic-clonic onvulsions i ' 19,31.32, clearly have 
a favourable prognosis. These two syndromes 
of childhood epilepsy, with a good prognosis 
both for control with medication and sustained 
remission when drugs are subsequently with- 
drawn, are probably responsible for the 
general observation that patients whose seiz- 
ures begin early in life, and are promptly con- 
trolled, have the best prognosis of continued 
remission after AED withdrawal. Various 
clinical measures of severity of epilepsy (seiz- 
ure type or types, total duration of epilepsy, 
maximum seizure frequency, seizure duration, 
etc.) are predictive of relapse in children and to 
some extent in adults. No other clinical 
features are of known predictive value in 
adults nor is there any consensus that the out- 
come is influenced by the period of remission 
prior to withdrawal, provided this is more than 
2 years, nor the rate of withdrawal (in all re- 
ported studies this was more of less gradual). 
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Reference/year Retro- (R) or Patients number Remission 
prospective (P) and relapse rate period (years) 
study and one N q 
control (C) group 
Age during Follow up 
withdrawal (years) (years) 
Yahr, 1952 - -  26 46 >2 
Zenker, 1957 - -  117 21 0.5-9 
Strobos, 1959 - -  41 46 >2 
Juul- Jensen, 1964, 1968 R + P 196 40 >2 
Loiseau, 1972 R 250 50 - -  
Tudor, 1973 R 82 15 >2/3 
Holowach-Thurston, 1972, 1982 R + P 148 28 >4 
Oller-Daurella, 1975, 1977, 1981 R 780 29 >5 
Janz, 1976, 1983 R 232 62 >2 
Foerster, 1978 R 114 31 >2/3 
Rodin, 1980 R 32 6 >3 
Van Heycop ten Ham, 1980 R 151 32 >5 
Overweg, 1980, 1982, 1985, 1987 P 62 66 >3 
Todt, 1981, 1984 P 433 36 1-4 
Emerson, 1981 P 68 26 >4 
Shinnar, 1985 P 88 25 >2 
Wallis, 1985, 1987 P 122 38 >2 
Broecker, 1985, 1986 P 112 75 >5 
Bouma, 1987 R 116 22 >2 
Arts, 1987 R 146 25 >2 
Callaghan, 19~b P 92 34 >2 
Matricardi, 1989 R 425 12 >2 
Chadwick, 1991 P 503 41 >2 
Chadwick, 1991 C 510 22 >2 
Gherpelli, 1992 P 70 29 >2 
4-20 >1 
- -  6.6 
5-18 5-12/22 
- -  0.5-26 
adult >2 
- -  2 - 5  
adults >5 
18-59 >7-12  
child >3 
6-22 0.5-6 
child 0.5-6 
child + adult 0.5-5 
adult 
child 0.75-10 
child 1.25-9.5 
child + adult 0.5-5 
child 1.6-12 
child + adult 2 
child + adult 2 
child 0.25-3.4 
Published figures disagree about the probability of patients avoiding relapse on withdrawal. 
Table 2: Possible risk factors for seizure recurrence 
Gender 
Age of seizure onset 
Age at last seizure 
Age at randomization 
Seizure type or types 
Number of seizures before control 
Duration of seizure-period after start AED-treatment 
Duration of treatment 
Duration of epilepsy 
Duration of seizure-free period prior to withdrawal 
Number of antiepileptic drugs 
Type of AEDs during withdrawal 
Dosages and serum levels of AEDs 
Seizures only at awakening 
Seizures only while asleep 
Status epilepticus 
Family history of epilepsy 
Seizures associated with other neurologic illness 
Mental retardation 
Psychological dysfunction 
Psychiatric disorder 
Previous attempted withdrawal 
EEG abnormalities 
Duration of withdrawal 
The medication prior to withdrawal and par- 
ticularly the blood levels, might be expected to 
relate to the severity of epilepsy, but appears to 
be considered in only a few studies 33'4a'44'47'52. 
These studies did in fact demonstrate a greater 
risk of relapse in children and in adults when 
their blood levels of AED were high. In all 
studies except in Shinnar's study a correlation 
was found between the drug level prior to with- 
drawal and the risk of subsequent seizure 
recurrence 44. 
An abnormal inter-ictal EEG has been 
repeatedly cited as predictive of relapse after 
AED withdrawal. Only four investigations (all 
in children) offer any evidence to support his 
view 33'41'44'46. Indeed many investigators 
excluded from their studies patients whose 
initial EEGs were abnormal or they abandoned 
AED withdrawal if the EEG deteriorated when 
medication was reduced. 
Although numerous variables (Table 2) 
might be of prognostic importance, our knowl- 
edge about the significance of demographic-, 
genetic-, aetiological-, pathophysiological- nd 
treatment-related risk factors remained ex- 
tremely poor. 
It is apparent hat several of the primary 
variables considered in Table 2 show a signifi- 
cant association with outcome, but even 
reports from the same institution could not 
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agree on which clinical variables are predic- 
tive, and no single variable could provide a 
basis for reliable prediction as'44. 
The predictive value of the EEG fares a little 
better than the clinical features. To determine 
whether combinations of variable existed that 
would be of greater predictive reliability, mul- 
tivariate analysis was performed in several 
studies 33'43'44"47"51'56. In a critical review 
Wallis (1987) has given explanations for the 
discrepancies found between different studies 
such as bias in the patient selection, difficul- 
ties in diagnostic classification resulting in 
grouping together of patients with forms of epi- 
lepsy with widely varying prognoses and a 
small number of patients in some of the 
trials 5°. 
Most studies have provided some estimates 
of the average risk of seizure recurrence during 
and after AED withdrawal. However, average 
risks may not be relevant o an individual with 
epilepsy. 
Epilepsy is not a single disease entity with 
one treatment and one prognosis. When speak- 
ing in general about this heterogeneous group 
of disorders with a wide variety of prognoses it
should be better to use the term 'epilepsies' 
instead of the word 'epilepsy'. Therefore, there 
is a need for more precise individual prediction 
of risk. Only a few study-groups have devel- 
oped a prognostic index 43'47"~s. The population 
studied by Overweg and colleagues was 
selected (patients from an epilepsy centre) and 
small and it is emphasized that the criteria 
used are applicable only to the particular type 
of patients tudied. A few years after this first 
attempt, Chadwick and co-workers developed a 
prospective index, derived from the only ran- 
domized study. So far, this model provides the 
best available information for patients if drug 
withdrawal is being considered 5s. Both study- 
groups found the EEG to be of no predictive 
value to the risk of seizure recurrence. This 
most conflicting variable, the EEG, will be dis- 
cussed below. 
ELECTROENCEPHALOGRAPHY 
The EEG is a valuable diagnostic tool, particu- 
larly during the initial evaluation of epilepsy, 
but it is the record of a short finite period 79's° 
and it would be difficult to justify on any scien- 
tific grounds a decision to prolong daily admin- 
istrations of AED on the basis of the EEG 
alone, in the absence of other important fac- 
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tors. Many neurologists take into account he 
EEG together with other clinical variables in 
deciding whether to withdraw or continue 
AED treatment. If drug withdrawal is under- 
taken, the EEG may be repeated on the 
reasonable, but unproved, assumption that a 
deteriorating record provides early warning of 
clinical relapse, which may be avoided by re- 
storing medication. The only study with a 
series of EEG recordings prior to drug with- 
drawal (a standard registration of 30 minutes 
including a 5-minute period of hyperventi- 
lation and photic stimulation, a sleep tracing 
and a 6-hour telemetric recording), followed by 
EEGs when the dosage of each drug had been 
halved, again when reduced to zero, and 4 
months after withdrawal of all drugs did not 
support the above-mentioned assump- 
tion 35'4"3'47. Neither the initial EEGs nor 
control registrations during withdrawal were 
predictive of relapse in this group of patients 
with partial seizures. However, the question 
whether AED should be discontinued if the 
EEG is abnormal remained controversial. 
Although an abnormal inter-ictal EEG has 
been repeatedly cited as predictive of relapse 
during or after AED withdrawal only a few 
studies offer any evidence to support this 
view 33'44'46'53. Indeed many investigators 
excluded from their studies patients whose 
initial EEGs were abnormal or abandoned 
AED withdrawals if the EEG deteriorated 
when medication was reduced. The studies in 
which EEG findings were predictive involved 
mainly children with idiopathic generalized 
epilepsy. Despite all (mostly a-priori) mean- 
ings about the predictive value of the EEG 
prior to and during drug withdrawal, the pre- 
ponderance of evidence indicates that an 
abnormal EEG (spiky and not-spiky abnor- 
malities) is not associated with an increased 
risk of seizure-recurrence in adults and in chil- 
dren with a localization-related epilepsy. In 
children and adults with an idiopathic general- 
ized epilepsy (e.g. absence-attacks and seizures 
belonging to the juvenile myoclonus epilepsy) 
and in photo-sensitive patients the EEGs are 
positively associated with the outcome of drug 
withdrawal sl-8~. 
Apart from the limitations of the EEG- 
registrations, the interpretation of the EEG 
may vary from observer to observer s4. This 
variability is influenced by specific reader 
characteristics. Various investigators employ 
different definitions of epileptiform activity 
and use different recording techniques both 
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leading to different interpretations of the 
EEGs. 
REMARKS ABOUT THE PREDICTIVE VALUE 
OF THE EEG 
Definitions 
From Gastaut's definition of paroxysmal epi- 
leptiform activity 'A wave or group of waves 
constituting the EEG presentation of an epi- 
leptic discharge which appears and disappears 
randomly and is characterized by a frequency, 
morphology or amplitude that clearly differen- 
tiates it from the background activity of the 
EEG' the impression could be gained that 
every paroxysmal discharge is epileptiform, 
which is not true. 
For the purpose of antiepileptic drug with- 
drawal studies the definition of epileptiform 
activity conforms with that in Gastaut's dic- 
tionary of epilepsy s2 and in addition with the 
opinion of Zivin and Ajmone Marsan s°, in prac- 
tice the discharges classified as epileptiform 
are limited to spikes and sharp waves with and 
without slow components. 
Zivin and Ajmone Marsan used the topogra- 
phical distribution as a criterion in addition to 
the paroxysmal character of the events °. They 
separated three main groups of epileptiform 
discharges, namely: (1) bilateral diffuse {gen- 
eralized), (2) bilateral non-diffuse (i.e. limited 
to one or two regions, synchronous or indepen- 
dent}, and (3) focal or partial. 
Limitations of the EEG-recording 
A frequently underestimated limitation of 
extracranial EEG recordings derives from the 
fact that the voltage of electrical potentials 
generated by the brain drops inversely pro- 
portionally to the square of the distance s6. 
Inter-ictal and ictal scalp recordings often 
provide limited information on the side and 
dimension of a discharging lesion for three 
major reasons 87. 
1. Only 1/6-1/5 of the total cerebral cortex is 
accessible to the conventional EEG. The 
depth of fissures or sulci and mesial as well 
as inferior surfaces of the hemispheres are 
not directly accessible. 
2. A scalp-derived signal can be projected from 
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a distant source and is therefore sometimes 
a misleading localizing sign. 
3. The biophysical requirements for appear- 
ance of spikes or sharp waves in ictal dis- 
charges are not always fulfilled at the 
scalp s~. 
Pathophysiology 
The importance of the EEG to present concepts 
of epilepsy and for the classifications of the epi- 
lepsies and the epileptic seizures would be dif- 
ficult to exaggerate. There is nevertheless 
little justification for the extrapolation under- 
lying the belief that inter-ictal epileptiform 
discharges are meaningful measures of sever- 
ity. A lack of association between the outcome 
of drug withdrawal and epileptiform EEG 
activity may appear surprising, but only if one 
accepts the widespread and unsubstantiated 
assumption that the presence and amount of 
inter-ictal epileptiform activity is closely 
related to seizure frequency, severity and prog- 
nosis of epilepsy. However, one should re- 
consider the assumption that the interictal 
discharge rate should be expected to reflect 
seizure frequency. Inter-ictal discharges are 
often dramatic, of high voltage, generalized 
and prolonged. By contrast, particularly in the 
partial epilepsies, the EEG changes seen at 
seizure onset often consist of electrodecremen- 
tal events of inconspicuous runs of rhythmic 
activity without a spiky waveform, this serv- 
ing to emphasize the dissociation between epi- 
leptiform inter-ictal EEG discharges and 
clinical seizures. 
Epileptogenesis involves a succession of 
events in which at least three distinct levels of 
organization can be recognized {Table 3). The 
epileptogenic neuron or neuronal population 
exhibits almost continuous electrophysiologi- 
cal abnormality. In the context of such a model 
{Table 3) the relationship between seizure fre- 
quency and the inter-ictal EEG will largely 
depend upon seizure propensity. 
Inter-ictal discharges registered with surface and 
with intra-cranial recordings 
In all AED-withdrawal studies the predictive 
value of the EEG is based upon surface EEG 
recordings. EEG registrations with depth elec- 
trodes as used in the pre-operative screening 
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Table 3: Three levels of epileptogenesis 7'~-9° 
Pathophysiology Expression 
I Cellular Paroxysmal 
epileptogenesis* depolarization 
shifts 
Seizure 
threshold§ 
II Synchronous Paroxysmal 
dyscharges in {epileptiform or 
neuronal not) activity in 
populations- EEG or SEEG 
Seizure 
propensity§ 
III Larger or specific Clinical seizure 
populations and in the EEG 
recruited-'., seizure activity 
Inot necessarily 
spikes or sharp 
waves} 
* At the cellular level the neurons in the epileptogenic 
foci appear to exhibit almost continuous abnormal 
activity; phenomena as paroxysmal depolarization shifts 
have been intensively investigated "9'9°. 
t Less attention has been devoted to the somewhat higher 
level of organization which determines the occurrence in 
much larger neuronal populations of synchronous 
discharges detectable as inter-ictal epileptiform (or 
paroxysmal not epileptiform) activity in the EEG (Figs 1 
and 2). 
The following level of organization determines the 
clinical expression of abnormal discharges and 
corresponds to Rodin's seizure propensity. 
§ Seizure threshold and propensity differ between 
generalized and localization-related pilepsy syndromes. 
for epilepsy surgery have shown that patterns 
recordable in deep cortical structures usually 
cannot be picked up on the scalp s6's7"91-93. 
In Figs 1 and 2 the discrepancy that can exist 
between depth and surface EEG recordings is 
illustrated. Figure 1 shows continuous dis- 
charges in the deep structures, at the same 
time the scalp EEG (Fig. 2) is normal with one 
exception, a sharp wave that easily could be 
missed or not recognized as a specific epilepti- 
form activity. 
Transition to the third level of epilepto- 
genesis, clinical expression as an ictal event, 
appears also to involve the crossing of a 
threshold (see also pathophysiology). Possibly 
there are patients with effective inhibitory 
mechanisms showing numerous inter-ictal dis- 
charges which rarely find clinical expression. 
By contrast, lack of such inhibition may result 
in a larger proportion of discharges producing 
clinical effects o that relatively few discharges 
are inter-ictal. 
Obviously the first two stages of epilepto- 
genesis are necessary for the third to occur but 
this second threshold may account for the fre- 
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quent lack of positive correlation between seiz- 
ure frequency and inter-ictal discharge rate. 
False positive and false negative EEG findings 
False positive and false negative findings are 
matter over which there are a number of 
misunderstandings. Spikes, sharp waves and 
particularly spike or sharp and slow wave com- 
plexes are commonly registered during seiz- 
ures and in the inter-ictal record of patients 
with epilepsy. They may however also occur in 
the EEGs of people who do not apparently have 
epileptic seizures s°. Conversely a seizure may 
be accompanied by an EEG change which is 
related to the fit but does not have the charac- 
teristic wave form. One may for instance see a 
run of focal theta activity of appropriate distri- 
bution during partial seizures and think this 
activity is not 'epileptiform' in the sense of 
being spiky, however, it is clearly 'epileptic' in 
the sense that it is a reflection of the fit. 
The same phenomena re seen in inter-ictal 
surface recordings, often bursts of irregular 
slow wave activity without sharp waves, 
activity that is not specific 'epileptiform' in the 
sense of being spiky. In Figs 3 and 4, a surface 
and a depth recording in the same patient and 
at the same time are shown. The 'not specific 
epileptiform activity' picked up with the sur- 
face electrodes actually reflects true epilepti- 
form activity in the depth. 
Association between epileptiform discharges 
and overt seizures 
There are well-known epilepsy syndromes with 
a closed association between the amount of dis- 
charges and clinical or sub-clinical epileptic 
seizures, as juvenile myoclonic epilepsy s2, 
photosensitive pilepsy s3 and childhood ab- 
sence epilepsy sl. Even if patients with these 
syndromes are seizure-free for 2, 3 or even 
more years, but the EEGs consist epileptiform 
discharges, drug withdrawal will not succeed 
because of seizure recurrence. It is remarkable 
that this firm association exists in the above- 
mentioned generalized seizure disorders. On 
the other hand, most of the partial seizure dis- 
orders do not have such a clear association be- 
tween clinical and EEG features. 
Although functional abnormalities, both 
electrophysiological and biochemical, are con- 
tinually present in the epileptic brain tissue, it 
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is only at intervals ranging from tens of milli- 
seconds to hours or even days that synchronous 
discharges become sufficiently widespread to 
be detectable with EEG electrodes. Only a frac- 
tion (and sometimes none} of these discharges 
are associated with overt clinical seizures. The 
mechanism underlying discharges detectable 
in the EEG are poorly understood, and less is 
known about the factors determining whether 
or not they produce clinical manifestations. 
While it is reasonable to expect hat correction 
of the underlying neuronal dysfunction by 
medication or by spontaneous remission should 
necessarily abolish both EEG discharges and 
seizures, it seems naive to suppose that this is 
the only mechanism by which a patient can 
become seizure-free. Any change in the liab- 
ility of neuronal discharge giving rise to 
clinical manifestations (described by Rodin as 
'seizure propensity'} would result in a dis- 
sociation between EEG findings and clinical 
state v. Most findings so far suggest that in 
many patients remission of epilepsy does not 
reflect a reduction in neuronal functional ab- 
normality but rather a diminution in seizure 
propensity. 
The practice of continuing antiepileptic drug 
medication in patients who have long been 
seizure free simply on account of an abnormal 
EEG, or resuming medication if epileptiform 
activity increases during antiepileptic drug 
withdrawal, is clearly not justified. 
Long-term EEG/video-monitoring 
In the course of previous studies of long-term 
monitoring 47'94'9'~ it had emerged that some 
patients exhibited numerous brief seizures 
which were not readily recognized either by 
the patient or by those about them without 
help of simultaneous EEG registration. To 
reduce the risk of such patients, who are 
wrongly supposed to be seizure-free, being 
included in a AED withdrawal procedure, long- 
term monitoring could be carried out prior to 
AED withdrawal. The importance of this 
measure is highlighted by the fact that in a 
group of 72 seizure-free patients, nine (11%) 
were demonstrated, even within a brief period 
of some 5 to 6 hours of monitoring, not to be 
seizure-free 4v. Eight of them exhibited EEG 
discharges accompanied by short periods of 
impairment of consciousness, with or without 
myoclonic movements, of which both they 
themselves and their relatives had been un- 
aware. In the whole group five patients were of 
low normal intelligence, which may explain 
why they themselves were unaware of the 
short periods of impairment of consciousness. 
The value of the long-term EEG monitoring in 
clinical practice which has been emphasized 
over one decade ago by several authors is once 
more confirmed 94-97. Video monitoring of be- 
haviour during long-term EEG telemetry 94 
and continuous assessment of cognitive func- 
tions by performance tests 9'~'9s indicate that 
runs of generalized spike wave complexes are 
usually accompanied by either behavioural- or 
cognitive changes and may thus virtually be 
equated with seizure themselves 9 . Another 
point of interest is the finding that four of 
these nine patients were photosensitive whilst 
three exhibited self-induction by slow eye- 
closure 99-t°1. So, when the question of with- 
drawing antiepileptic drugs arises, it is advis- 
able to do long-term EEG monitoring. In cases 
of generalized epileptiform discharges, even 
when impairment of consciousness is not clini- 
cally apparent, it is worthwhile performing 
tests to demonstrate any transient cognitive 
impairment 95,98. 
GUIDELINES FOR ANTIEPILEPTIC DRUG 
WITHDRAWAL 
General procedure prior to and during drug 
withdrawal 
On admission to withdraw the antiepileptic 
medication each patient's case history should 
be reviewed and augmented as necessary and a 
full neurological examination has to be per- 
formed. A full diagnostic EEG examination 
has to be carried out to ascertain the classifi- 
cation of the seizure type(s) and the classifi- 
cation of the epilepsy. In addition long-term 
telemetric EEG registrations of some hours 
duration has to be considered. Blood levels of 
all antiepileptic drugs used by the patient 
must be checked and drug withdrawal com- 
menced following a standardized procedure. 
The patients have to be followed up clinically 
for at least 2 years after stopping all medi- 
cation. In the event of recurrence of seizures 
the patient has to be immediately withdrawn 
from further drug discontinuation and further 
management has to be adapted to the individ- 
ual circumstances. In most instances this 
involved at least partial restoration of the pre- 
vious medication, but in most cases it has to be 
considered appropriate to continue treatment 
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Table 4: Proposal for an AED withdrawal schedule, showing 2-weekly steps from initial dose 
J. Overweg 
PB 300 250 200 150 100 75 50 25 
PRM 1750 1500 1250 1000 750 500 250 125 
PHT 400 350 300 250 200 150 100 50 
ESM 1500 1250 1000 750 500 250 
CBZ 1600 1400 1200 1000 800 600 400 200 
VPA 2400 2100 1800 1500 1200 900 600 300 
Abbreviations: PB, phenobarbitone; PRM, primidone; PHT, phenytoin; ESM, ethosuximode; CBZ, carbamazepine; VPA, 
valproate. 
at a reduced level, or even at a later date, to 
continue AED withdrawal. 
Each patient has to be instructed in the 
event of relapse immediately to resume the 
previous medication and to contact he general 
practitioner or medical specialist. Further 
management thereafter is individualized. All 
patients could be also supplied with two rec- 
tioles of 10 mg diazepam to be used in the event 
of a series of seizures or a threatening status 
epileptics. 
Drug withdrawal procedure 
The drugs can be divided into groups of first 
(the major AEDs as carbamazepine, phenytoin 
and valporate), second (ethosuximide, pheno- 
barbitone) and third choice (primidone or a 
benzodiazepine). Not yet mentioned are rela- 
tively new compounds like oxcarbazepine, 
lamotrigine, vigabitrine, felbamate and other 
new AEDs, drugs to be expected first choice 
AEDs. This classification is based both on 
general epileptological practice and in particu- 
lar the relative efficacy and side effects. Pre- 
sumably the drugs of third choice are of some 
benefit to certain patients, otherwise their 
registration as antiepileptic drug would be 
unjustified. In patients taking multiple drugs, 
any drug of third choice has to be withdrawn 
first, then those of second choice and finally of 
first choice. Where a patient is receiving two 
drugs of first choice, then the order of with- 
drawal has to be determined by their probable 
efficacy in the type of epilepsy in question. The 
period of time over which the various drugs 
will be withdrawn could follow the schedule set 
out in Table 4 taking into account he charac- 
teristics of the various different antiepileptic 
drugs. 
Duration of withdrawal 
The rate of withdrawal is related to the initial 
medication in such a way that a large dose is 
withdrawn over a longer period of time, pass- 
ing from eventual polypharmacy to mono- 
therapy, ending in a single daily dose in the 
final phase. According to Todt the length of the 
reduction period is an important factor and the 
relapse risk decreases when withdrawal is 
undertaken over at least 6 months 34A1. 
According to the results of Juul- Jensen and 
Tennison, by contrast he length of the period 
of discontinuation does not exert any influence 
on the frequency of recurrence 16' lo2. 
Figure 5 shows the time relation between 
drug withdrawal and seizure recurrence in the 
study of Van Heycop ten Ham and in the study 
of  Overweg 31'43. Most recurrences are seen in 
close relation to the attempted iscontinuation 
of medication. Some two-thirds of the patients 
who relapsed did so during withdrawal and 
80~ within 3 months after stopping all medi- 
cation. In the following 10 years there was a 
progressive decline in the frequency of the 
recurrences. There was no difference in the 
risk of relapse between a 4 months (Overweg) 
and a 30 months (Van Heycop ten Ham) period 
of drug discontinuation. It is reasonable to 
expect hat, if an anticonvulsant level becomes 
inadequate, regardless over what period of 
time, and the patient still has a seizure dis- 
order, he will sooner or later have an attack. 
An exception is provided by the effects of rapid 
AED withdrawal per se, which can provoke 
generalized convulsions, particularly in the 
case of barbiturates and benzodiazepines. It 
can be concluded that the duration of AED- 
withdrawal depends on the number of drugs 
taken and their pharmacokinetic properties. 
Withdrawal time (weeks or months) does not 
influence the outcome 16'43A°2. 
DISCUSSION 
In general, the findings in the literature on 
AED withdrawal confirm that no single vari- 
able is reliably predictive of outcome. The 
proposition that epileptiform EEG activity 
should be predictive of relapse has been 
regarded by most previous investigators to be 
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attempted iscontinuation of medication. Some two-thirds of the patients who relapsed did so during withdrawal increasing to 
80% three months after stopping all AEDs. 
so self-evident that it would be ethically unac- 
ceptable to put it to the test. Only a few 
prospective studies including adults 43'47'5°''~6 
have addressed this issue all with negative 
conclusions. Despite widely held opinions to 
the contrary, these findings are hardly surpris- 
ing as, except in children and particularly in 
absence seizures, and in photosensitive epi- 
lepsy both in children and adults, there is little 
evidence that the EEG provides a useful 
measure of seizure liability or of antiepileptic 
drug effects ms-l°5. Although functional abnor- 
malities, both electrophysiological and bio- 
chemical, are continually present in epileptic 
brain tissue, it is only at intervals ranging 
from tens of milliseconds to hours or even days 
that synchronous discharges become suf- 
ficiently widespread tobe detectable with EEG 
electrodes~06.107. 
Only a fraction (sometimes none) of these 
discharges is associated with overt clinical 
seizures. The mechanisms underlying dis- 
charges detectable in the EEG are poorly 
understood, and less is known of the factors 
determining whether or not they produce clini- 
cal manifestations. While it is reasonable to 
expect that correction of the underlying 
neuronal dysfunction by medication or by 
spontaneous remission should necessarily 
abolish both EEG discharges and seizures, it 
seems naive to suppose that this is the only 
mechanism by which a patient can become 
seizure-free. Any change in the liability of 
neuronal discharge to give rise to clinical 
manifestations, described as seizure propen- 
sity 7, would result in dissociation between 
EEG findings and clinical state. In many 
patients remission of epilepsy does not reflect a 
reduction in neuronal functional abnormality 
but rather a diminution in seizure propensity. 
In fact there is a weak association between the 
more florid types of epileptiform discharge and 
relapse and this might have attained statisti- 
cal significance in a larger sample. Studying 
EEG and other early predictors of epilepsy 
remission EEG findings other than generalized 
epileptiform activity were not significantly 
related to either endpoint l°s. 
The question arises if these patients with 
generalized epileptiform discharges have to be 
considered seizure-free as has been pointed out 
previously in this paper. 
Prognostic index for seizure recurrence in 
seizure-free patients 
Currently the best available aid for counsel- 
ling patients who suffered from epileptic seiz- 
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ures and who have been seizure-free for at 
least 2 years is the model developed by Chad- 
wick and co-workers 5s. This prognostic model 
(Table 5) represents an important application 
of data from the only randomized study of 
AED-withdrawal from patients in remission. 
As such this model provides the best available 
information when discontinuation of medi- 
cation is considered. 
Table 5: Prognostic index for seizure-recurrence within 1 and 
2 years after continuing AED-treatment or after AED- 
withdrawal ,~ 
Starting score (all patients) - 175 
Age 16 or older add 45 
Taking more than one AED add 50 
Seizures after start of AED treatment add 35 
History of 'primary' or 'secondarily' 
generalized tonic-clonic seizures add 35 
History of myoclonic seizures add 50 
EEG in the past year 
not available add 15 
abnormal add 20 
Period free from seizures ¢PFFS)lin years) add 200/PFFS 
Total score T T 
T/100 
Divide T by 100 and exponentiate z = e 
Probability of seizure recurrence 
Continued treatment 
by one year 1-0.89 ~ 
by two years 1-0.79 ~ 
AED withdrawal 
by one year 1-0.692 
by two years 1-0.60 ~ 
SUMMARY 
A question of practical clinical importance is 
whether AEDs can be withdrawn after the 
patient has been seizure-free for a given period 
of time. Opinions vary concerning the relation- 
ship between the relapse rate and seizure 
types. For absence attacks the risk of relapse is 
low, as is the risk of relapse in partial seizure 
in the benign epilepsy of childhood with Rolan- 
dic spikes. There is a trend toward an increase 
in the relapse rate in patients with partial seiz- 
ures, particularly complex partial seizures. 
Almost all authors agree that the relapse risk 
is greatest in patients with partial seizures 
with secondary generalization (to tonic-clonic 
seizures) and in juvenile myoclonus epilepsy. 
The total number of seizures and the duration 
of the seizure disorder prior to remission seems 
to be related to the likelihood of relapse. The 
J. Overweg 
l iterature is fairly unanimous that the time 
between the first and the last seizure (i.e. 
duration of the illness) as well as severe 
mental subnormality are related to the risk of 
relapse. The length of the seizure-free period is 
a determinant for good outcome. There is a 
trend discernible toward a higher risk of 
relapse when blood levels of antiepileptic drugs 
were high. The total number of AEDs used 
prior to drug discontinuation is a factor that 
influences the outcome. Although, in general, 
the value of the EEG is doubtful in predicting 
seizure recurrence during and after antiepilep- 
tic drug discontinuation, there are at least 
three prospective studies (all in children) 
which indicate a higher relapse risk when the 
EEG prior to discontinuation of medication 
shows epileptiform (including paroxysmal s ow 
wave) activity. It is advisable to perform long- 
term EEG/video monitoring prior to drug 
discontinuation. In cases of generalized epilep- 
tiform discharges, even when impairment of 
consciousness i  not clinically apparent, it is 
worthwhile attempting to demonstrate tran- 
sient cognitive impairment. 
SUGGESTIONS FOR FUTURE RESEARCH 
Only randomized and multicentre prospective 
studies of relapse during and after drug with- 
drawal versus continuing drug treatment 
would help to determine predictors of seizure 
recurrence. The first step in future studies is to 
avoid heterogeneity in seizure- and epilepsy 
types to be studied. As long as patients with 
forms of epilepsy with a widely varying prog- 
nosis will be grouped together in AED-with- 
drawal trials, the outcome of these trials will 
never reach consensus concerning the relapse 
rate and concerning the possibility to predict 
relapse in individual patients. 
ACKNOWLEDGEMENTS 
The author is indebted to Joke Westenbroek, 
Tineke van E1 and Dagmar Kildentoft for help- 
ing to prepare the manuscript. 
REFERENCES 
1. Hauser, W.A. and Kurland, L.T. The epidemiology of
epilepsy in Rochester, Minnesota, 1935 through 1967. 
Epilepsia 1975; 16: 1-66. 
Antlepileptic drug withdrawal 
2. Annegers, J.F., Hauser, W.A. and Elveback, L.R. 
Remission of seizures and relapse in patients with 
epilepsy. Epilepsia 1979; 20: 729-737. 
3. Juul-Jensen, P. and Foldsprang, A. Natural history of 
epileptic seizures. Epilepsia 1983; 24: 297-312. 
4. Goodridge, D.M.G. and Shorvon, S.D. Epileptic seiz- 
ures in a population of 6000: I. Demography, diag- 
nosis and classification, and role of the hospital ser- 
vices. British Medical Journal 1983; 287: 641-645. 
5. Goodridge, D.G.M. and Shorvon, S.D. Epileptic seiz- 
ures in a population of 6000: II. Treatment and prog- 
nosis. British Medical Journal 1983; 287: 645-647. 
6. Hauser, W.A. and Hesdorffer, D.C. Epilepsy, Fre- 
quency, Courses and Consequences. Epilepsy Foun- 
dation of America, Landover Maryland, Demos, 1990. 
7. Rodin, E.A. The Prognosis of Patients with Epilepsy. 
Springfield, Thomas, 1968. 
8. Rodin, E.A. Various prognostic aspects in patients 
with epilepsy. Folia Psychiatrica Neurologica Japo- 
nica 1978; 32: 407-418. 
9. Rutgers, M.J. Geneeskundige en maatschappelijke 
aspecten van de zorg voor epilepsiepatienten in 
Nederland IThesis). Erasmus University, Rotterdam, 
1984. 
10. Shorvon, S.D. and Reynolds, E.H. The prognosis of 
new referrals with epilepsy. In: Epilepsy: British 
Danish-Dutch Meeting (Eds T.A. Betts, R.H. 
Hoppener and B. Pedersen). British Journal Clinical 
Practice 1982; ISuppl. 18): 133-135. 
11. Elwes, R.D.C., Johnson, A.L., Shorvon, S.D. and 
Reynolds, E.H. The prognosis for seizure control in 
newly diagnosed epilepsy. New England Journal of 
Medicine 1984; 311: 944-947. 
12. Yahr, M.D., Sciarra, D., Carter, S. and Merritt, H.H. 
Evaluation of standard anticonvulsant therapy in 
three hundred and nineteen patients. Journal Ameri- 
can Medical Association 1952; 150: 663-667. 
13. Zenker, C., Groh, C. and Roth, G. Probleme und 
Erfahrungen beim Absetzen antikonvulsiver Ther- 
apie. Neue Osterreichische Zeimssehrifl i~r Kinder- 
heilkunde 1957; 2: 152-163. 
14. Merritt, H.H. Medical treatment in epilepsy. British 
Medical Journal 1958; 1: 666-669. 
15. Strobos, R.R.J. Prognosis in convulsive disorders. 
Archives of Neurology 1959; 1: 108-117. 
16. JuuI-Jensen, P. Frequency of recurrence after discon- 
tinuance of anti-convulsant therapy in patients with 
epileptic seizures. Epilepsia 1964; 5: 352-363. 
17. Juul-Jensen, P. Frequency of recurrence after discon- 
tinuance of anti-convulsant therapy in patients with 
epileptic seizures: a new follow-up study after five 
years. Epilepsia 1968; 9: 11-16. 
18. Loiseau, D., Henry, P. and Prissard, A. Consider- 
ations sur arret des traitements anti-epileptiques. 
Bordeaux Med. 1972; 19: 2613-2640. 
19. Holowach, J., Thurston, D.L. and O'Leary, L. Prog- 
nosis in childhood epilepsy: follow-up study of 148 
cases in which therapy had been suspended after pro- 
longed anticonvulsant control. New England Journal 
of Medicine 1972; 286: 169-174. 
20. Oller-Daurella, L. and Marquez, J. Survey of 100 epi- 
leptics who have not had seizures for 10 years or 
more. Epilepsia 1972; 13: 161-170. 
21. Fridljanskij, A. Partieller und kompletter Abbau der 
Behandlung bei Patienten mit Epilepsie. Journal of 
Neuropathology and Psychiatry, Korsakow 1973; 73: 
1706-1710. 
33 
22. Oller-Daurella, L., Pamies, R. and Oiler, F.V. Re- 
duction of discontinuance of antiepileptic drugs in 
patients eizure-free for more than five years. In: Epi- 
leptology: Proceedings of the Seventh International 
Symposium on Epilepsy, Berlin (West), June 1975 
{Ed. D. Janz). Stuttgart, Gerog Thieme, 1976: pp. 
218-227. 
23. Janz, D. and Sommer-Burkhardt, E.-M. Discontinu- 
ation of antiepileptic drugs in patients with epilepsy 
who have been seizure-free for more than two years. 
In: Epileptology: Proceedings of the Seventh Inter- 
national Symposium on Epilepsy, Berlin (West}, June 
1975. lEd. D. Janz). Stuttgart, Gerog Thieme 1976; 
pp. 228-234. 
24. Oller-Daurella, L., Oiler, F.-V.L. and Paroles, R. 
Clinical, therapeutic, and social status of epileptic 
patients without seizures for more than five years. In: 
Epilepsy. The Eighth International Symposium. lEd. 
J.K. Penry). New York, Raven Press 1977; pp. 69- 
75. 
25. Marques-Assis, J. Supresso do tratamento medica- 
mentoso has epilepsias. Arquives de Neuropsiquiatria 
1977; 35: 112-118. 
26. Rodin, E.A., John, G., Kobiljak, J. and Green, M.A. 
Discontinuation of anticonvulsant medications in 
remitted epileptic patients. Electroencephalography 
and Clinical Neurophysiology 1977; 43: 905. 
27. Foerster, C. and Schmidberger, G. Prognostische 
Wertigkeit von EEG-Verlaufsuntersuchungen b i 
Kindern mit Anfallsrezidiven ach Absetzen der 
antikonvulsiven Therapie. In: Epilepsie 1978 (Ed. H. 
DooseL Stuttgart, Thieme, 1978: pp. 252-255. 
28. Tudor, J., Milea, S., Bicescu, E. and Ivana, D. Catam- 
nestic study of childhood epilepsy. Revue Roumainede 
Neurologie 1979; 10: 341-352. 
29. Kristof, M. Die Prognose der Epilepsie und die Taktik 
der Beendigung der antiepileptischen Therapie. PSY- 
chiatre Neurologie Medizinische Psvchologie rLeipzig) 
1979; 31: 449-457. 
30. Rodin, E.A. and John, G. Withdrawal of anticonvul- 
sant medications in successfully treated patients with 
epilepsy. In: Advances in Epileptology: The Xth Epi- 
lepsy International Symposium. (Eds J.A. Wada and 
J.K. Penry). New York, Raven Press, 1980: pp. 183- 
186. 
31. Van Heycop ten Ham, M.W. Complete recovery from 
epilepsy? Discontinuation ofanti-epileptics after five 
or more seizure-free years. Huisarts en Wetenschap 
1980: 23: 309-311. 
32. Oller-Daurella, L., Sanchez, M.E. and Oiler, F.-V.L. 
Discontinuance of antiepileptic therapy in epileptics 
seizure free for more than 5 years. Abstract XIIth 
Epilepsy International Symposium, Copenhagen, 
September 6-10, 1980. 
33. Emerson, R., D'Souza, R.J., Vining, E.P., Holden, 
K.R., Mellits, E.D. and Freeman, J.M. Stopping medi- 
cation in children with epilepsy: predictors of out- 
come. New England Journal of Medicine 1981; 304: 
1125-1129. 
34. Todt, H. Zur Spaetprognose kindlicher Epilepsien-- 
Ergebnisse iner prospektiven Langsschnitt studie. 
Deutsche Gesundheitwesen 30: 1981; Heft 48: pp. 
2012-2016. 
35. Overweg, J., Rowan, A. J., Binnie, C.D., Oosting, J. 
and Nagelkerke, N.J.D. Prediction of seizure recur- 
rence after withdrawal of antiepileptic drugs. In: Ad- 
vances in Epileptology: XIIth Epilepsy International 
34 
Symposium. (Eds M. Dam, L. Gram and J.K. Penryl. 
New York, Raven Press, 1981: pp. 503-508. 
36. Holowach-Thurston, J., Thurston, D.L., Hixon, B.B. 
and Keller, A.J. Prognosis in childhood epilepsy: ad- 
ditional follow-up of 148 children 15 to 23 years after 
withdrawal of anticonvulsant therapy. New England 
Journal of Medicine 1982; 306: 831-836. 
37. Janz, D., Kern, A., Moessinger, J.-J. and Puhlmann, 
H.-U. Relapse prognosis during and after reduction of 
medication i  the treatment ofepilepsy. Paper pre- 
sented at the Epilepsy Manifestation i The Hague 
{The Netherlands}, 1982. 
38. Foerster, C. and Schmidberger, G. Prognosis in child- 
hood epilepsy after discontinuation of therapy. 
Monatsschrift Kinderheilkunde 1982; 130: 225-228. 
39. Janz, D., Kern, A., Moessinger, H.J. and Puhlmann, 
H.-U. Ruckfall-Prognose waehrend und nach Reduk- 
tion der medikamente b t Epilepsiebehandlung. I : 
Epilepsi 1981. (Eds H. Reinschmidt, R. Rentz and J. 
Jungmanz} Stuttgart, Thieme 1983: pp. 17-24. 
40. Janz, D., Kern, A., Moessinger, H.J. and Puthmann, 
V. Rueckfall-Prognose nach Reduktion der Medika- 
mente bet Epilepsiebehandlung. Nervenarzl 1983; 54: 
525-529. 
41. Todt, H. The late prognosis of epilepsy in childhood: 
results of a prospective follow-up study. Epilepsia 
1984; 25: 137-144. 
42. Cavazzuti, G.B., Nalin, A. and Galli, V. Withdrawal 
of anticonvulsant therapy in 457 subjects with epi- 
lepsy started in childhood. European Federation of 
Child Neurology Societies IEFCNS). Symposium 
Noordwijkerhout, The Netherlands; 13-17 June 
1983. 
43. Overweg, J. Withdrawal ofantiepileptic drugs in seiz- 
ure-free adult patients. Prediction of outcome. Thesis, 
University of Amsterdam, Amsterdam, Rodopi: 1985. 
44. Shinnar, S., Vinning, E.P.G., Mellits, E.D., D'Souza, 
B.J., Holden, K., Baumgardner, R.A. and Freeman, 
J.M. Discontinuing antiepileptic medication i  chil- 
dren with epilepsy after two years without seizures. 
New England Journal of Medicine 1985; 308: 976- 
980. 
45. Broeker, H. Zur Prognose behandelter Epilepsien im 
Erwachsenalter (unter besonderer Berucksichtigung 
des Serumspiegelverhaltens vor Beginn und waeh- 
rend des stufenweisen Absetzens der Antiepileptika), 
Thesis, Dresden, 1985. 
46. Pestre, M., Loiseau, P., Larrieu, E. and Cohadon, S. 
Stopping medication i adolescent epileptic patients. 
In: Abstracts Epilepsy International Symposium 
Hamburg, Ciba-Geigy, Basel, 1985. 
47. Overweg, J., Binnie, C.D., Oosting, J. and Rowan, 
A.J. Clinical and EEG prediction of seizure recur- 
rence following antiepileptic drug withdrawal. Epi- 
lepsy Research 1987; 1: 272-283. 
48. Broeker, H. Zur Problematik ether Fuehrersche- 
ingewaehrung bet oder nach Absetzen der Antiepilep- 
tika. Verkehrsmedizin 1987; 34: 224-237. 
49. Bouma, P.A.D., Peters, A.C.B., Arts, R.J.H.M., 
Stijnen, Th. and Van Rossum, J. Discontinuation f 
antiepileptic therapy: aprospective study in children. 
Journal of Neurology Neurosurgery and Psychiatry 
1987; 50: 1579-1583. 
50. Wallis, W.E. Withdrawal of anticonvulsant drugs in 
seizure-free pileptic patients. Clinical Neurophar- 
macology 1987; 10: 423-433. 
51. Arts, W.F.M., Visser, L.H., Loonen, M.C.B., Tijam, 
J. Overweg 
A.T., Stroink, H. Stuurman, P.M. and Poortvliet, 
D.C.J. Follow-up of 146 children with epilepsy after 
withdrawal of antiepileptic therapy. Epilepsia 1988; 
29: 244-250. 
52. Callaghan, N., Garrett, A. and Goggin, T. With- 
drawal of anticonvulsant drugs in patients free of 
seizures for two years. New England Journal of Medi- 
cine 1988; 318: 942-946. 
53. Matricardi, M., Brinciotto, M. and Benedetti, P. Out- 
come after discontinuation f antiepileptic drug ther- 
apy in children with epilepsy. Epilepsia 1989; 30: 
582-589. 
54. Dean, J.C. and Pentry, J.K. Discontinuation f anti- 
epileptic drugs. General principles. In: Antiepileptic 
Drugs, third edition, IEds R. Levy, B. Mattson, B. 
Meldrum, J.K. Penry and F.E. Dreifuss). New York, 
Raven Press, 1989. 
55. Dean, J.C. and Penry, J.K. Rate of reduction of anti- 
epileptic drugs in chronic epilepsy. Epilepsia 1991; 
32: IS3): 63. 
56. Chadwick, D. Randomized study of antiepileptic drug 
withdrawal in patients with remission. Lancet 1991; 
337: 1175-1180. 
57. Gherpelli, J.L.D, Kok, F., dal Forno, S., Elkis, L.C., 
Lefevre, B.H.W. and Diamant, A.J. Discontinuing 
medication i  epileptic hildren: A study of risk fac- 
tors related to recurrence. Epilepsia 1992; 33: 681- 
686. 
58. Chadwick, D. Prognostic index for recurrence ofseiz- 
ures after remission of epilepsy. British Medical 
Journal 1993; 306: 1374-1378. 
59. Grosz-Tsur, V. and Shinnar, S. Discontinuing antiepi- 
leptic drug treatment. In: The Treatment of Epilepsy. 
lEd. E. WyllieL" Philadelphia, London, Lea and 
Febiger 1993: pp. 858-866. 
60. Meinardi, H. and Steel, L.M.K. Side-effects ofantiepi- 
leptic drugs. In: Handbook of Clinical Neurology, vol. 
15. (Eds P.J. Vinken and G.W. BruynL Amsterdam, 
North Holland Publishing Company, 1974; pp. 705- 
737. 
61. Reynolds, E.H. Chronic antiepileptic toxicity: a 
review. Epilepsis 1975; 16: 319-352. 
62. Reynolds, E.H. How to avoid chronic toxicity. In: 
Chronic Toxicity of A ntiepileptic Drugs. IEds J. Oxley, 
D. Janz and H. MeinardiL New York, Raven Press 
1983; p. 300. 
63. Schmidt, D. Adverse Effects of Antiepileptic Drugs. 
New York, Raven Press 1982; p. 226. 
64. Oxley, J., Janz, D. and Meinardi, H. Chronic Toxicity 
of Antiepileptic Drugs. New York, Raven Press 1983; 
p. 3O0. 
65. Janz, D. Antiepileptic drugs and pregnancy: altered 
utilization patterns and teratogenesis. Epilepsia 
1982; 23: 53-63. 
66. Shapiro, S., Hartz, S.C., Siskind, V., Mitchell, A.A., 
Slone, D., Rosenberg, L., Monson, R.R., Heinomen, 
O.P., Idanpaan-Heikkila, J., Haro, S. and Saxen, L. 
Anticonvulsants and parental epilepsy in the devel- 
opment of birth defects. Lancet 1976; 1: 272-275. 
67. Lindhout, D. Teratogenesis in maternal epilepsy. 
New aspects of prevention. {Thesis} Amsterdam, 
1985. 
68. Lindhout, D., Omtzigt, J.G.C. and Cornel, M.C. Spec- 
trum of neural-tube defects in 34 infants prenatally 
exposed to antiepileptic drugs. Neurology 1992; 42 
(Suppl) 5: 111-118. 
69. Swaab, D.F. and Mirmiran, M. Possible mechanisms 
AntiepilepUc drug withdrawal 
underlying the teratogenic effects of medicines on the 
developing brain. In: Neurobehavioral Teratology. 
tEd. J. Yanai}. Amsterdam, Elsevier 1984; pp. 55-71. 
70. Swaab, D.F. and Mirmiran, M. The influence of 
chemicals and environment on brain devlopment. In: 
Behavioral teratology. Proceedings World Congress 
UNAPEI; Prevention of Physical and Mental Con- 
genital Defects. Part B: Epidemiology, Early Detection 
and Therapy, and Environmental Factors. tEd. M. 
Narios}. New York, Liss, 1985: pp. 447-451. 
71. Swaab. D.F. Influence of fetal and neonatal environ- 
ment on physical, psychological, and intellectual de- 
velopment: workshop summary. In: Behavioral 
Teratology. Proceedings World Congress UNAPEI; 
Prevention of Physical and Mental Congenital Defects, 
Part B: Epidemiology, Early Detection and Therapy, 
and Environmental Factors. lEd. M. Marios}. New 
York, Liss, 1985: pp. 463-467. 
72. Yerby, M.S. Treatment of epilepsy during pregnancy. 
In: The Treatment of Epilepsy: Principles and Prac- 
tices. (Ed. E. Wyllie}. Philadelphia, Lea and Febiger, 
1993: pp. 844-857. 
73. Christiansen, P. and Lund, M. Sexual potency, testi- 
cular function and excretion of sexual hormones in 
male epileptics. In: Epileptology. lEd. D. Janzl. Stutt- 
gart, Thieme, 1977: pp. 190-191. 
74. Trimble, M.R. and Thompson, P.J. Anticonvulsant 
drugs, cognitive function and behavior. Epilepsia 
1983; 24 ($1): 55-62. 
75. Aldenkamp, A.P., Alpherts, W.C.J., Moerland, M.C., 
Ottevanger, N. and Van Parijs, J.A.P. Controlled 
release carbamazepine: cognitive side-effects in 
patients with epilepsy. Epilepsia 1987; 28 507-514. 
76. Trimble, M.R. Antiepileptic drugs, cognitive function, 
and behavior in children: evidence from recent 
studies. Epilepsia 1990; 31 ($4): pp. 30-34. 
77. AIdenkamp, A.P., Alpherts, W.C.J., Blennow, G., 
Elmqvist, D., Heijbel, J., Nilsson, H., Sandstedt, P., 
Tonby, B., Wahlander, L. and Wosse, E. Withdrawal 
of antiepileptic medication--effects on cognitive func- 
tion in children--the results of the multicentre 
'Holmfrid' study. Neurology 1993; 43: pp. 41-51. 
78. Pitlick, W.H. Antiepileptic Drug Interactions. Demos. 
Publication New York, 1989. 
79. Ajmone Marsan, C. and Zivin, L.S. Factors related to 
the occurrence oftypical paroxysmal bnormalities in 
the EEG records of epileptic patients. Epilepsia 1970; 
11: 361-381. 
80. Zivin, L. and Ajmone Marsan, C. Incidence and prog- 
nostic significance of 'epileptiform' activity in the 
EEG of non-epileptic subjects. Brain 1968; 91: 751- 
778. 
81. Dalby, M.A. Epilepsy and three per second spike and 
wave rhythms: a clinical, electroencephalographic 
and prognostic analysis of 346 patients. Acta Neuro- 
logica Scandinavica 1969; Suppl 45: 6. 
82. Janz, D. Juvenile myoclonic epilepsy. In: Comprehen- 
sive Epileptology (Eds M. Dam and L. Gram). New 
York, Raven Press, 1990; pp. 171-185. 
83. Binnie, C.D. Electroencephalography. In: A Textbook 
of Epilepsy (4th edition}. (Eds J. Laidlaw, A. Richens 
and D. Chadwick}. Edinburgh, Churchill Livingstone, 
1992. 
84. Williams, G.W., Luders, H.O., Birckner, A., 
Goormastic, M. and Klass, D.W. Interobserver varia- 
bility in EEG interpretation. Neurology 1985; 35: 
1714-1719. 
35 
85. Gastaut. J  Dictionary of Epilpesy Part 1: Definitions. 
World Health Organization, Geneva, 1973; p. 75. 
86. GIoor, P. Contributions of electroencephalography 
and electrocorticography to the neurosurgical treat- 
ment of the epilepsies. In: Neurosurgical Management 
of the Epilepsies (Eds D.P. Purpura, J.K. Penry and 
R.D. Waiters). New York, Raven Press. Advances in 
Neurology 1975; 8; pp. 59-105. 
87. Wieser, H.G. Electroclinical Features of the Psycho- 
motor Seizure. Stuttgart/New York, Gustav Fischer, 
1983. 
88. Binnie, C.D. The inter-ictal EEG. In: What is Epi- 
lepsy? (Eds M.R. Trimble and E.H. Reynolds}. Edin- 
burgh, Churchill Livingstone, 1986; pp. 116-125. 
89. Speckmann, E.-J., Elger, C.E. and Altrup, U. Neuro- 
physiologic basis of the EEG. In: The Treatment 
of Epilepsy: Principles and Practices (Ed. E. Eylie}. 
Philadelphia, Lea and Febiger 1993; pp. 185-201. 
90. Heinemann, U. and Jones, R.S.G. Neurophysiology. 
In: Comprehensive Epileptology (Eds M. Dam and L. 
Gram}. New York, Raven Press, 1990; pp. 17-42. 
91. Quesney, L.F. Extracranial EEG evaluation. In: Sur- 
gical Treatment of the Epilepsies tEd. J. Engel). New 
York, Raven Press, 1987; pp. 129-171. 
92. Engel, J. Recent advances in surgical treatment of 
temporal lobe epilepsy. In: Future Research in Epilep- 
tology (Eds J. Overweg, A.P. Aldenkamp and H.M. de 
Boer). Acta Neurologica Scandinavica 1992; 86 (Suppl 
140): pp. 71-80. 
93. Quesney, L.F. Extratemporal epilepsy: Clinical pres- 
entation, pre-operative EEG localization and surgical 
outcome. In: Future Research in Epileptology IEds J. 
Overweg, A.P. Aldenkamp and H.M. de Boer}. Acta 
Neurologica Scandinavica 1992:86 (Suppl 140}; pp. 
81-94. 
94. Binnie, C.D., Rowan, A.J., Overweg, J. et al. Tele- 
metric EEG and videomonitoring in epilepsy. Neurol- 
ogy tNY) 1981; 31: 298-303. 
95. Aarts, J.H.P., Binnie, C.D., Smit, A.M. and Wilkins, 
A.J. Selective cognitive impairment during focal and 
generalized epileptiform EEG activity. Brain 1984; 
107: 293-308. 
96. Penry, J.K., Porter, R.J. and Dreifuss, F.E. Simul- 
taneous recording of absence seizures with video tape 
and electrocephalography: a study of 374 seizures in 
48 patients. Brain 1975; 98: 427-440. 
97. Stalberg, E. Experiences with long-term telemetry in 
routine diagnostic work. In: Quantitative Analytic 
Studies in Epilepsy (Eds P. Kellaway and I. Petersen}. 
Raven Press, New York, 1976: pp. 269-277. 
98. Binnie, C.D. Detection of transitory cognitive impair- 
ment during epileptiform EEG discharges: problems 
in clinical practice. In: Epilepsy and Behaviour (Eds 
13.M. Kulig, H. Meinardi and G. Stores}. Swets and 
eitlinger, Lisse, 1980: pp. 91-97. 
.. Darby, C.E., De Korte, R.A., Binnie, C.D. and 
Wilkins, A.J. The self-induction of epileptic seizures 
by eye closure. Epilepsia 1980; 21: 31-42. 
100. Binnie, C.D., Darby, C.E., De Korte, R.A. et al. Self- 
induction of epileptic seizures by eye-closure: inci- 
dence and recognition. Epilepsia 1979; 21: 202. 
101. Overweg, J. and Binnie, C.D. Pharmacotherapy of 
self-induced seizures. In: Abstracts, 12th Epilepsy In- 
ternational Symposium. Copenhagen, Denmark 1980. 
102. Tennison, M.B. Role of taper for antiepileptic drugs. 
Epilepsia 1986; 27: 640. 
103. Binnie, C.D., Aarts, J.H.P., Van Bentum-De Boer, 
36 
P.T.E. et al. Monitoring at the lnstituut voor Epilep- 
siebestrijding Meer en Bosch. In: Long-Term Moni- 
toring in Epilepsy (Eds J. Gotman, J.R. Ives and P. 
Gloor) Electrocephalography and Clinical Neurophy- 
siology Supplement 37. Elsevier, Amsterdam 1985: 
pp. 341-355. 
104. Van Wieringen. A., Binnie, C.D., De Boer, P.T.E. et 
al. Visual and spectral analysis of EEGs during anti- 
epileptic drug trials. Electrocephalography and Clini- 
cal Neurophysiology 1985; 61: S214. 
105. Van Wieringen, A. Effects of antiepileptic drugs on 
the electroencephalogram background and epilepti- 
form activity. EEG handbook (New series, vol 1, 
J. Overweg 
Clinical Neurophysiology of Epilepsy). (Eds J.A. 
Wada and R.J. Ellingson~. Amsterdam, Elsevier 
Science Publishers 1990; pp. 433-456. 
106. Abraham, K. and Ajmone Marsan, C. Patterns ofcor- 
tical discharges and their relation to routine scalp 
electrencephalography. Electroencephalography and 
Clinical Neurophysiology 1958' 10: 447-461. 
107. Wieser, H.G. Electroclinical Features of the P.2vcho- 
motor Seizure. Stuttgart, New York, Fischer, 1983. 
108. Shafer, S.Q., Hauser, W.A.. Annegers, J.F. et al. EEG 
and other early predictors of epilepsy remission: a 
community study. Epilepsia 1988: 29: 590-600. 
